Key result
32P radioactive beta-emitting stents reduced intrastent restenosis in a dose-related manner (16% to 0%), but intralesion restenosis remained high (41%-52%) due to an edge effect.
Why the study?
Does 32P radioactive beta-emitting stent implantation reduce restenosis in patients with coronary artery disease?
Population
82 patients with coronary artery disease (91 lesions)
Design
Cohort
Follow-up
6 months
Authors
Loading...
Edge restenosis precludes 32P stent adoption; leaves open whether design modifications can overcome this in trials.
Cohort (n=82)
Does 32P radioactive beta-emitting stent implantation reduce restenosis in patients with coronary artery disease?
While radioactive beta-emitting stents reduce intrastent neointimal hyperplasia in a dose-dependent manner, they are associated with a high rate of intralesion restenosis at the stent edges.
Albiero et al. (2000) conducted a cohort in Coronary Artery Disease (n=82). 32P radioactive beta-emitting stents was evaluated on Intrastent binary restenosis and intralesion restenosis. 32P radioactive beta-emitting stents reduced intrastent restenosis in a dose-related manner (16% to 0%), but intralesion restenosis remained high (41%-52%) due to an edge effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: